Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.
COVID‐19
SARS‐CoV‐2
antibody responses
omicron variant
solid organ transplant
vaccine
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
02
2022
revised:
11
04
2022
accepted:
12
04
2022
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
5
5
2022
Statut:
epublish
Résumé
Solid organ transplant recipients (SOTR) receiving post-transplant immunosuppression show increased COVID-19-related mortality. It is unclear whether an additional dose of COVID-19 vaccines can overcome the reduced immune responsiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. We analysed humoral immune responses against SARS-CoV-2 and its variants in 53 SOTR receiving SARS-CoV-2 vaccination. Following the initial vaccination series, 60.3% of SOTR showed no measurable neutralisation and only 18.9% demonstrated neutralising activity of > 90%. More intensive immunosuppression, antimetabolites in particular, negatively impacted antiviral immunity. While absolute IgG levels were lower in SOTR than controls, antibody titres against microbial recall antigens were higher. By contrast, SOTR showed reduced vaccine-induced IgG/IgA antibody titres against SARS-CoV-2 and its delta variants and fewer linear B-cell epitopes, indicating reduced B-cell diversity. Importantly, a third vaccine dose led to an increase in anti-SARS-CoV-2 antibody titres and neutralising activity across alpha, beta and delta variants and to the induction of anti-SARS-CoV-2 CD4 Only a small subgroup of solid organ transplant recipients is able to generate functional antibodies after an initial vaccine series; however, an additional vaccine dose resulted in dramatically improved antibody responses against all SARS-CoV-2 variants except omicron where antibody responses and neutralising activity remained suboptimal.
Identifiants
pubmed: 35505864
doi: 10.1002/cti2.1391
pii: CTI21391
pmc: PMC9052011
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1391Informations de copyright
© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Am J Transplant. 2021 Jul;21(7):2509-2521
pubmed: 33278850
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
PLoS One. 2021 Apr 29;16(4):e0250796
pubmed: 33914803
Vaccines (Basel). 2021 Jul 03;9(7):
pubmed: 34358153
Commun Biol. 2021 Dec 16;4(1):1389
pubmed: 34916602
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Transpl Infect Dis. 2020 Oct;22(5):e13407
pubmed: 32654303
Am J Transplant. 2021 Mar;21(3):1295-1303
pubmed: 33259686
Vaccines (Basel). 2021 Jul 04;9(7):
pubmed: 34358154
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Transplantation. 2022 May 1;106(5):e262-e263
pubmed: 35175241
Am J Transplant. 2021 Aug;21(8):2876-2884
pubmed: 33835707
Sci Immunol. 2021 Jun 15;6(60):
pubmed: 34131023
N Engl J Med. 2021 Sep 23;385(13):1233-1234
pubmed: 34379913
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Med. 2021 Jul;27(7):1178-1186
pubmed: 33953384
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
Am J Transplant. 2022 Jan;22(1):322-323
pubmed: 34331842
Am J Transplant. 2021 Dec;21(12):3980-3989
pubmed: 34347934
J Infect Dis. 2015 Jul 1;212(1):137-46
pubmed: 25589334
Blood Adv. 2020 Oct 13;4(19):4864-4868
pubmed: 33031540
JAMA. 2022 Jan 25;327(4):319-320
pubmed: 34935863
Arthritis Res Ther. 2012;14(3):R110
pubmed: 22571761
Br J Haematol. 2020 Jul;190(2):e64-e67
pubmed: 32420609
Am J Transplant. 2020 Nov;20(11):3008-3018
pubmed: 32780493
Arthritis Res Ther. 2015 Apr 03;17:92
pubmed: 25890338
Immunopharmacology. 2000 May;47(2-3):85-118
pubmed: 10878285
Cancer. 2020 Dec 1;126(23):5069-5076
pubmed: 32910456
Clin Infect Dis. 2021 Dec 6;73(11):e4090-e4099
pubmed: 32766815
Am J Transplant. 2021 Aug;21(8):2913-2915
pubmed: 33864722
Pharmaceuticals (Basel). 2021 Oct 17;14(10):
pubmed: 34681278
J Immunol. 2021 Jan 1;206(1):109-117
pubmed: 33208457
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Ann Intern Med. 2021 Sep;174(9):1336-1338
pubmed: 34029487
Blood. 2020 Dec 24;136(26):3033-3040
pubmed: 33367546
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
Clin Infect Dis. 2021 Dec 6;73(11):2000-2008
pubmed: 34134134
Clin Transplant. 2022 Jan;36(1):e14495
pubmed: 34569101
JCI Insight. 2019 Jan 24;4(2):
pubmed: 30674728
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Am J Transplant. 2021 Jul;21(7):2522-2531
pubmed: 33443778
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Viruses. 2021 Apr 25;13(5):
pubmed: 33923063
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Kidney Int. 2020 Dec;98(6):1549-1558
pubmed: 32853631
Am J Transplant. 2021 Jun;21(6):2254-2261
pubmed: 33590675
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
Chest. 2020 Jul;158(1):97-105
pubmed: 32304772
Clin Infect Dis. 2022 Mar 23;74(6):1093-1096
pubmed: 34166499
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056